

# Kenneth B Gordon

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6867888/kenneth-b-gordon-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77  
papers

5,988  
citations

34  
h-index

77  
g-index

82  
ext. papers

7,238  
ext. citations

8.9  
avg, IF

5.47  
L-index

#	Paper	IF	Citations
77	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). <i>Lancet, The</i> , <b>2008</b> , 371, 1665-74	40	1296
76	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1318-28	59.2	530
75	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 345-56	59.2	505
74	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 418-431	4.5	405
73	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1029-1072	4.5	296
72	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. <i>Lancet, The</i> , <b>2018</b> , 392, 650-661	40	283
71	Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 114-135	4.5	267
70	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 136-44	59.2	212
69	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1313-1321	59.2	171
68	Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. <i>Cancer</i> , <b>1995</b> , 75, 2168-73	10.73	153
67	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 1073-1113	4.5	145
66	Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2013</b> , 27, 1535-45	4.6	137
65	Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 66, 241-51	4.5	129
64	A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 304-14	4.3	128
63	A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 1176-82	4.5	87
62	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1445-1486	4.5	79
61	Clinical meaningfulness of complete skin clearance in psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 77-82.e7	4.5	65

60	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 161-201	4.5	63
59	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1348-1358	4	58
58	Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. <i>JAMA Dermatology</i> , <b>2018</b> , 154, 676-683	5.1	56
57	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 487-498	4.0	51
56	Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 775-804	4.5	47
55	Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 432-470	4.5	46
54	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 475-486	4.0	44
53	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 2437-2446.e1	4.3	42
52	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2102	59.2	41
51	Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2017</b> , 31, 1004-1013	4.6	40
50	Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. <i>British Journal of Dermatology</i> , <b>2018</b> , 178, 132-139	4	40
49	Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 1940-1949	4.6	39
48	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 936-945	4.5	38
47	Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. <i>JAMA Dermatology</i> , <b>2016</b> , 152, 661-9	5.1	37
46	Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. <i>British Journal of Dermatology</i> , <b>2014</b> , 170, 705-15	4	37
45	Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 320-328	4	36
44	Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 76, 1045-1053.e3	4.5	35
43	Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. <i>Advances in Therapy</i> , <b>2020</b> , 37, 364-380	4.1	28

42	Serious infections in hospitalized patients with psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 287-96	4.5	27
41	Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2013</b> , 169, 1337-41	4	24
40	A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2016</b> , 30, 864-5	4.6	18
39	Unmet needs in the treatment of psoriasis. <i>European Journal of Dermatology</i> , <b>2014</b> , 24, 523-32	0.8	17
38	Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 79, 294-301.e6	4.5	16
37	Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, 301-309	4.6	16
36	Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 767-76	4.6	14
35	IL-23 inhibitors for moderate-to-severe psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2018</b> , 37, 158-162	1.4	14
34	The inpatient burden of psoriasis in the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 75, 33-41	4.5	14
33	Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. <i>British Journal of Dermatology</i> , <b>1997</b> , 136, 415-20	4	13
32	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , <b>2020</b> , 21, 881-890	7.1	12
31	The experience of pain and redness in patients with moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2015</b> , 26, 401-5	2.8	11
30	Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. <i>British Journal of Dermatology</i> , <b>1997</b> , 136, 415-420	4	10
29	Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-10	2.8	9
28	Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2018</b> , 32, 1297-1304	4.6	8
27	Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2676-7	27.4	8
26	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	8
25	Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization. <i>Dermatologic Surgery</i> , <b>1996</b> , 22, 723-8	1.7	8

24	SAT0130 Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn's disease. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 514.3-515	2.4	7
23	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 652-662	4	7
22	Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). <i>British Journal of Dermatology</i> , <b>2018</b> , 179, 984-986	4	6
21	Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2017</b> , 28, 3-7	2.8	6
20	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.. <i>Dermatology and Therapy</i> , <b>2022</b> , 12, 495	4	6
19	Understanding therapeutic pathways and comorbidities in psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2014</b> , 33, S20-3	1.4	5
18	Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. <i>JAMA Dermatology</i> , <b>2020</b> , 156, 1344-1353	5.1	5
17	Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatology</i> , <b>2019</b> , 46, 1141-1152	1.6	4
16	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	4
15	Risankizumab in moderate-to-severe plaque psoriasis. <i>Immunotherapy</i> , <b>2019</b> , 11, 1357-1370	3.8	4
14	Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 31, 763-768	2.8	4
13	Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry. <i>Dermatology</i> , <b>2021</b> , 237, 46-55	4.4	3
12	Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 1030-1037	4.5	2
11	Cutaneous Manifestations of Chronic Liver Disease. <i>Clinics in Liver Disease</i> , <b>2020</b> , 24, 351-360	4.6	2
10	Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. <i>Archives of Dermatology</i> , <b>1997</b> , 133, 691-3		2
9	Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2019</b> , 4, 147-152	1.1	1
8	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.. <i>Dermatology and Therapy</i> , <b>2022</b> , 12, 561	4	1
7	Update on New and Emerging Therapies in the Management of Psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2015</b> , 34, S34-6	1.4	1

6	Defining drug-free remission of skin disease in patients with plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1484-1487	4	1
5	Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , <b>2021</b> , 1-9	2.8	1
4	225 An oral, selective inhibitor of tyrosine kinase 2, BMS-986165, improves molecular, cellular, and clinical biomarkers associated with efficacy in moderate to severe psoriasis <b>2019</b> ,		1
3	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , <b>2020</b> , 29, 369-380	3.7	0
2	Psoriasis and associated diseases <b>2014</b> , 141-157		
1	The International Psoriasis Council Presents Top Five Psoriasis Research Articles for July 2010. <i>Psoriasis Forum</i> , <b>2011</b> , 17a, 275-279		